Compare Boeing Co (BA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs State Street SPDR S&P Biotech ETF — how do they compare? Boeing Co trades at $217.74 (market cap $171.15B), while State Street SPDR S&P Biotech ETF trades at $155.16. The key difference: Boeing Co pays a 0.03% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Boeing Co nearer its low. Which is the better fit depends on your goals.
| BA | XBI | |
|---|---|---|
Market Cap | $171.15B | — |
Volume | 7,591,579 | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $252.15 | $164.28 |
52-Week Low | $179.12 | $85.16 |
Enterprise Value | $197.46B | — |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $215.51, down 3.05% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 85.18 but improving revenue and net income, reaching $89.46B and $2.24B in 2025, respectively. Recent news highlights potential order wins, including discussions with Riyadh Air for additional 787s, while technical indicators point to support near $209.
Outlook remains cautiously optimistic with a consensus price target of $268.33, implying 24.5% upside, but risks include volatile cash flows, high debt, and ongoing operational challenges. Analyst sentiment is bullish with 66.7% buy ratings, though investors should monitor execution on delivery targets and margin improvements.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
